ZFA-Logo

Renal Sympathetic Denervation

german translation / full article

Simon Kostner

Question

To a patient who has an insufficient blood pressure control despite a quadruple therapy (ACE inhibitor, thiazide diuretic, beta-blocker and calcium antagonist) was offered by a specialist to have to undergo a renal sympathetic denervation abroad. Undecided, he asks the doctor whether he should risk this intervention. Can you recommend to him this procedure?

Answer

The renal sympathetic denervation as mini-invasive transfemoral procedure is a new treatment, of witch there is few data on efficacy and safety. Short and medium term, the method seems to provide a good reduction of blood pressure, and this without great risks. Long-term efficacy and safety is not known, nor the impact on cardiovascular morbidity and mortality. It should be explained to the patient that this intervention is not a substitute for medical treatment, but a possible supplementing therapy-resistant cases. It is most likely that he needs to continue the majority of his pills.


(State: 29.05.2015)

Latest Issue 2/2020

In Focus

  • Medical Assistants’ Perspectives on their Training Needs
  • Herpes Zoster Vaccination
  • What is Good Specialist Training?